Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

Journal of Clinical Investigation

Volumn 105, Issue 7, 2000, Pages 967-976

  Duda, Petra W ^a,b   Schmied, Mascha C ^a   Cook, Sandra L ^a   Krieger, Jeffrey I ^a   Hafler, David A ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERLEUKIN 13; INTERLEUKIN 5; T LYMPHOCYTE RECEPTOR;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CROSS REACTION; CYTOKINE RELEASE; DEGENERATION; DRUG EFFECT; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0034041863     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8970     Document Type: Article

References (38)

1. Hafler, D.A. 1999. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J. Clin. Invset. 104:527-529.
2. Windhagen, A., et al. 1995. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182:1985-1996.
3. Grewal, I.S., et al. 1996. Requirement for CD40 ligand in costimulation induction. T cell activation, and experimental allergic encephalomyelitis. Science. 273:1864-1867.
4. Lehmann, P.V., Forsthuber, T., Miller, A., and Sercarz, E.E. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358:155-157.
5. Windhagen, A., et al. 1998. Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis. J. Neuroimmunol. 91:1-9.
6. Yu, M., Johnson, J.M., and Tuohy, V.K. 1996. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 183:1777-1788.
7. Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A., and Weiner, H.L. 1994. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 265:1237-1240.
8. Evavold, B.D., and Allen, P.M. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 252:1308-1310.
9. Karin, N., Mitchell, D.J., Brocke, S., Ling, N., and Steinman, L. 1994. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J. Exp. Med. 180:2227-2237.
10. Pfeiffer, C., et al. 1995. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J. Exp. Med. 181:1569-1574.
11. Nicholson, L.B., Murtaza, A., Hafler, B.P., Sette, A., and Kuchroo, V.K. 1997. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc. Natl. Acad. Sci. USA. 94:9279-9284.
12. Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R., and Sela, M. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1:242-248.
13. Fridkis-Hareli, M., et al 1994. Direct binding of myelin basic protein and synthetic copolymer I to class II major histocompatibility complex molecules on living antigen-presenting cells: specificity and promiscuity. Proc. Natl. Acad. Sci. USA. 91:4872-4876.
14. Fridkis-Hareli, M., and Strominger, J.L. 1998. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J. Immunol. 160:4386-4397.
15. Brosnan, C.F., et al. 1985. Immunogenic potentials of copolymer I in normal human lymphocytes. Neurology. 35:1754-1759.
16. Teitelbaum, D., Fridkis-Hareli, M., Arnon, R., and Sela, M. 1996. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:209-217.
17. Ben-Nun, A., et al. 1996. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J. Neurol. 243:S14-22S.
18. Johnson, K.P., et al. 1998. Extended use of glatiramer acetate(Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 50:701-708.
19. Johnson, K.P., et al. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenrer, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 45:1268-1276.
20. Comi, G., and Filippi, M. 1999. The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MRJ in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment. Neurology. 52:A289. (Abstr.)
21. Lando, Z., Teitelbaum, D., and Arnon, R. 1979. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J. Immunol. 123:2156-2160.
22. Aharoni, R., Teitelbaum, D., and Arnon, R. 1993. T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur. J. Immunol. 23:17-25.
23. Aharoni, R., Teitelbaum, D., Arnon, R., and Sela, M. 1999. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking Proc. Natl. Acad. Sci. USA. 96:634-639.
24. Aharoni, R., Teitelbaum, D., Sela, M., and Arnon, R. 1997. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA. 94:10821-10826.
25. Fukaura, H., et al. 1996. Induction of circulating myelin basic protein and proteolipid protein specific TGF-β1 secreting T cells by oral administration of myelin in multiple sclerosis patients J. Clin. Invest. 98:70-77.
26. Sloan-Lancaster, J., and Allen, P.M. 1995. Significance of T-cell stimulation by altered peptide ligands in T cell biology. Curr. Opin. Immunol. 7:103-109.
27. Hemmer, B., et al. 1997. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J. Exp. Med. 185:1651-1659.
28. Ausubel, L.J., Krieger, J.I., and Hafler, D.A. 1997. Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99. J. Immunol. 159:2502-2512.
29. Critchfield, J.M., et al. 1994. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science. 263:1139-1143.
30. Allegretta, M., Nicklas, J.A., Sriram, S., and Albertini, R.J. 1990. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science. 247:718-721.
31. Zhang, J., et al. 1994. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179:973-984.
32. Bieganowska, K.D., et al. 1997. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J. Exp. Med. 185:1585-1594.
33. Kuchroo, V.K., et al. 1994. T cell receptor (TCR) usage determines disease susceptibility in experimental autoimmune encephalomyelitis: studies with TCR V beta 8.2 transgenic mice. J. Exp. Med. 179:1659-1664.
34. Marusic, S., and Tonegawa, S.M.S. 1997. Tolerance induction and autoimmune encephalomyelitis amelioration after administration of myelin basic protein-derived peptide. J. Exp. Med. 186:507-515.
35. Sloan-Lancaster, J., Evavold, B.D., and Allen, P.M. 1993. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363:156-159.
36. Evavold, B.D., Sloan-Lancaster, J., Wilson, K.J., Rothbard, J.B., and Allen, P.M. 1995. Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. Immunity. 2:655-663.
37. Windhagen, A., et al. 1995. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity. 2:373-380.
38. Jorgensen, J.L., et al. 1992. Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics. Nature. 355:224-230.